港股异动 | 四环医药(00460)午前涨超5% 轩悦宁®第三个适应症上市申请获NMPA批准

Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen its stock price increase by over 5% following the approval of its innovative drug, Pyrotinib tablets (brand name: XuanYueNing), for a new indication in the treatment of HR+/HER2- advanced breast cancer in China [1] Group 1: Company Developments - On March 3, Four Seasons Pharmaceutical announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib tablets in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1] - This approval marks the third indication for Pyrotinib in China, following its previous approvals for use in combination with Fulvestrant and as a monotherapy [1] - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and later lines, significantly expanding patient coverage and enhancing clinical value [1] Group 2: Market Impact - The approval is expected to effectively increase the drug's accessibility and clinical value, providing strong support for future sales growth [1] - As of the report, Four Seasons Pharmaceutical's stock price rose by 5.19%, reaching HKD 1.42, with a trading volume of HKD 19.4691 million [1]